估算白蛋白排泄率在慢性肾脏病中的预后价值:来自心脏与肾脏保护研究的结果
在心脏与肾脏保护研究(SHARP)中,对5552例基线未透析的慢性肾脏病患者比较估算白蛋白排泄率(eAER)与白蛋白肌酐比(ACR)对终末期肾病(ESRD)、血管事件和死亡的预测价值。中位随访4.8年,eAER与ACR对ESRD、血管事件及死亡风险的预测能力相似,eAER未改善风险预测。
要点
- 在5552例慢性肾脏病患者中,eAER与ACR对ESRD风险的预测能力相似,每10倍升高的RR分别为2.67与2.70。
- eAER与ACR对血管事件、血管性死亡和非血管性死亡的风险关联相似,两者均未提供额外预后信息。
- eAER未改善对ESRD、血管事件或死亡的风险预测。
核心结论
- 在本研究中,eAER未改善对ESRD、血管事件或死亡的风险预测。
研究设计与样本
- 研究为心脏与肾脏保护研究(SHARP)的事后分析,纳入5552例基线未透析的慢性肾脏病患者,采用Cox比例风险回归比较ACR与eAER的预后价值。
- eAER由ACR、性别、年龄和种族估算。
主要发现
- 中位随访4.8年,1959例发生ESRD,1204例发生血管事件,1130例死亡(641例非血管性死亡,369例血管性死亡,120例死因未知)。
- 校正年龄、性别和eGFR后,ACR和eAER每10倍升高的ESRD相对风险分别为2.70(95%CI 2.45-2.98)和2.67(95%CI 2.43-2.94)。
- 校正后,ACR和eAER每10倍升高的血管事件相对风险分别为1.37(95%CI 1.22-1.53)和1.36(95%CI 1.22-1.52)。
- 校正后,ACR和eAER每10倍升高的血管性死亡相对风险分别为1.64(95%CI 1.33-2.03)和1.62(95%CI 1.32-2.00);非血管性死亡相对风险分别为1.53(95%CI 1.31-1.79)和1.50(95%CI 1.29-1.76)。
- 对于ESRD风险、血管事件风险,ACR和eAER均未在对方基础上提供额外预后信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estimated albumin excretion rate (eAER) provides a better estimate of 24-h albuminuria than albumin:creatinine ratio (ACR). However, whether eAER is superior to ACR in predicting end-stage renal disease (ESRD), vascular events (VEs) or death is uncertain. METHODS: The prognostic utility of ACR and eAER (estimated from ACR, sex, age and race) to predict mortality, ESRD and VEs was compared using Cox proportional hazards regression among 5552 participants with chronic kidney disease in the Study of Heart and Renal Protection, who were not on dialysis at baseline. RESULTS: During a median follow-up of 4.8 years, 1959 participants developed ESRD, 1204 had a VE and 1130 died (641 from a non-vascular, 369 from a vascular and 120 from an unknown cause). After adjustment for age, sex and eGFR, both ACR and eAER were strongly and similarly associated with ESRD risk. The average relative risk (RR) per 10-fold higher level was 2.70 (95% confidence interval 2.45-2.98) for ACR and 2.67 (2.43-2.94) for eAER. Neither ACR nor eAER provided any additional prognostic information for ESRD risk over and above the other. For VEs, there were modest positive associations between both ACR and eAER and risk [adjusted RR per 10-fold higher level 1.37 (1.22-1.53) for ACR and 1.36 (1.22-1.52) for eAER]. Again, neither measure added prognostic information over and above the other. Similar results were observed when ACR and eAER were related to vascular mortality [RR per 10-fold higher level: 1.64 (1.33-2.03) and 1.62 (1.32-2.00), respectively] or to non-vascular mortality [1.53 (1.31-1.79) and 1.50 (1.29-1.76), respectively]. CONCLUSIONS: In this study, eAER did not improve risk prediction of ESRD, VEs or mortality.
引用
- Mafham MM, Staplin N, Emberson J, et al. Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrol Dial Transplant. 2018. PMID: 28088776. doi:10.1093/ndt/gfw396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。